The short version of solubility fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-23 and is reviewed periodically as new material appears.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Peptides are short chains of amino acids linked by amide bonds, and their storage stability depends on sequence, length, and three-dimensional structure. Chemical degradation can occur through hydrolysis, oxidation, deamidation, and aggregation, while physical changes such as precipitation or surface adsorption reduce recovery. Storage conditions are chosen to slow these processes without altering the peptide itself. Because peptides vary widely, no single condition suits every sequence, so laboratories often establish stability empirically for each batch.
Temperature is a primary factor because most degradation reactions proceed more slowly at lower temperatures. Lyophilized peptides are commonly held at -20 °C or below, although some sequences remain stable at 2–8 °C for limited periods. Moisture uptake during handling can accelerate hydrolysis, so sealed containers and desiccants are used. Solutions are generally less stable than powders and may require freezing at -80 °C or refrigeration, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation even when the storage temperature is otherwise suitable.
Light, oxygen, and pH influence peptide integrity through specific side-chain reactions. Methionine and cysteine residues are susceptible to oxidation, and tryptophan can degrade under strong light. Inert gas overlays and amber glass or opaque containers reduce these risks. pH affects charge, solubility, and the rate of deamidation or aggregation; a value that minimizes one pathway may increase another. The optimal pH and buffer for a given peptide are often determined experimentally, and open questions remain about predicting stability from sequence alone.
| Property | Value | Notes |
|---|---|---|
| Reconstitution solvent | Sterile water or aqueous buffer | Organic cosolvent may be needed for hydrophobic sequences |
| pH adjustment | Sequence-dependent | Test small volumes before preparing the full solution |
| Filtration | 0.22 µm sterile filter | Can remove particles but may bind or remove aggregates |
| Aliquot size | Single-use volume | Reduces repeated freeze-thaw cycles |
| Post-reconstitution storage | -20 °C to -80 °C | Follow supplier or protocol; avoid frost-free cycles |
Reconstitution introduces new variables. The solvent should match the peptide's solubility profile, and water or buffer quality matters because trace metals and microbes can alter results. Adding solvent gently down the vial wall minimizes foaming, which can denature some sequences. Mixing by gentle inversion or swirling is usually preferred over vigorous vortexing. If a peptide does not dissolve readily, adjusting pH or using a small amount of organic co-solvent may help, but such steps can also affect stability and should be documented.
Quality control links handling to measurable identity and purity. Reverse-phase high-performance liquid chromatography can separate peptide variants and reveal impurities. Mass spectrometry confirms molecular mass and can detect truncations or modifications. These methods are often paired with ultraviolet absorbance or amino acid analysis for concentration. Documentation of instrument settings, column type, and reference standards supports reproducibility. For research materials, acceptance criteria depend on the intended application, and no universal purity threshold applies to all peptides.
Shipping and short-term transfer require attention to temperature control and physical stability. Frozen solutions are commonly sent on dry ice, while lyophilized powders may travel with gel packs or insulated packaging. Thawing should be done slowly on ice or in a refrigerator, not by vigorous heating, and the solution should be mixed gently before use. Temperature loggers can document excursions during transit, but their presence does not prove that a peptide remained stable. Analytical checks such as chromatography or mass spectrometry can verify identity and purity after storage or shipping.
Reconstitution begins with selecting a solvent that dissolves the peptide without causing degradation. Water or aqueous buffer is suitable for many hydrophilic sequences, while hydrophobic peptides may require a small amount of organic solvent such as acetonitrile or dimethyl sulfoxide before dilution. The solvent is added to the vial rather than the powder being scraped out, and the mixture is swirled or inverted gently to avoid foaming. Complete dissolution should be confirmed visually, and insoluble material may indicate aggregation or impurities. Because solvent tolerance varies, published solubility information or a small test dissolution can guide handling.
Aseptic technique reduces microbial and particulate contamination when a peptide solution will be used in cell culture or other sensitive applications. Work in a clean area, use sterile containers and filtered tips, and avoid touching vial interiors. Preparing aliquots immediately after dissolution limits repeated temperature cycling, which is a common cause of aggregation and activity loss. Low-binding plastic tubes are preferred for peptides that adsorb to surfaces, especially hydrophobic or positively charged sequences. Labels should record identity, solvent, concentration, and preparation date so that later use can be traced.
== Artificial enzymes == New approaches to design artificial enzymes based on amino acids or peptides as characteristic molecular moieties have led to a significant expansion of the field of artificial enzymes or enzyme mimics. Recent results by the group of Rob Liskamp have shown that scaffolded histidine residues can be used as mimics of certain metalloproteins and -enzymes. The structural mimicry of certain copper proteins (e.g. hemocyanin, tyrosinase and catechol oxidase), containing type-3 copper binding sites, has been shown. This is a significant improvement since the use of scaffolded histidine residues is one step closer to the mimicry of enzymes by biologically relevant species.
Dyspnea (shortness of breath) exacerbated by exertion Cough, often persistent and sometimes severe Fatigue Tachypnea (rapid breathing) which is often labored Loss of appetite and weight loss Chest pain Fever Gradual darkening of skin (blue skin) Gradual dark shallow rifts in nails eventually leading to cracks as protein fibers within nail beds are destroyed In advanced cases, the following may also occur:
The liver is grossly divided into two parts when viewed from above – a right and a left lobe – and four parts when viewed from below (left, right, caudate, and quadrate lobes). The falciform ligament makes a superficial division of the liver into a left and right lobe. From below, the two additional lobes are located between the right and left lobes, one in front of the other. A line can be imagined running from the left of the vena cava and all the way forward to divide the liver and gallbladder into two halves. This line is called Cantlie's line. Other anatomical landmarks include the ligamentum venosum and the round ligament of the liver, which further divide the left side of the liver in two sections. An important anatomical landmark, the porta hepatis, divides this left portion into four segments, which can be numbered starting at the caudate lobe as I in an anticlockwise manner. From this parietal view, seven segments can be seen, because the eighth segment is only visible in the visceral view.
Sources: en.wikipedia.org
=== 1971-2000 === In 1971, Revlon acquired DCL BioMedical, a clinical laboratory business founded in 1968. In 1974, it changed its name to National Health Laboratories Incorporated. By 1977, it operated clinical testing laboratories in 13 cities and maintained auxiliary service centers and satellite laboratories in 15 other cities. In 1978, it acquired American Biomedical Corporation, giving it operations in the Southwestern United States and data processing technology. In 1985, Revlon was acquired by Ronald Perelman. Revlon divested its other businesses and a major stake in the company was acquired by MacAndrews & Forbes. In 1988, National Health Laboratories became a public company via an initial public offering on the NASDAQ exchange. In 1989, the company generated revenue of about US$400 million, with about US$70 million in earnings. In the early 1990s, worries about malpractice lawsuits led doctors to conduct more clinical testing before diagnosing, which increased business for the company. In 1990, the company's revenues reached US$500 million, with over US$70 million in earnings. In 1991, National Health Laboratories moved its listing from the NASDAQ to the New York Stock Exchange. In June 1992, the company offered to acquire Damon Corporation for $260 million in cash and stock. However, the company was outbid by Corning Inc., which acquired Damon for $370 million. By 1993, the company had 22 major laboratories. On March 8, 1994, National Health Laboratories Inc. reorganized as a holding company, National Health Laboratories Holdings Inc.
== History == Hydromorphone was first synthesized in Germany in 1921 and was subsequently patented in 1923. It was introduced to the mass market in 1926 under the brand name Dilaudid, indicating its derivation and degree of similarity to morphine (by way of laudanum).
== Effects == Unlike other KOR agonists, nalfurafine does not produce hallucinogenic effects in humans. Single intramuscular injections of up to 30 μg are well tolerated by humans, whereas a dose of 40 μg produced "moderate behavioral/psychological side effects" (possibly referring to sedation), though apparently did not produce any psychotomimetic or dysphoric effects. In rodents, a low dose of nalfurafine (10–40 μg/kg) was found not to produce conditioned place preference or aversion, though a high dose (80 μg/kg) did induce significant place aversion. The most common side effect of low-dose nalfurafine seen in clinical trials was insomnia (observed in 10–15% of patients), with few other adverse effects observed. In addition, tolerance to the antipruritic effects of nalfurafine was not found after treatment of patients with the drug for one year, and nalfurafine has shown no evidence of either physical nor psychological dependence in humans. The drug also shows lower evidence of tolerance for effects such as analgesia and sedation in animals relative to other KOR agonists. In animals, nalfurafine produces anti-scratch, antinociceptive, sedative, and diuretic effects.
== External links == Anorectics at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Mitchell, Kari (January 1997). "Anorexiant Agents: Considerations for Use" (PDF). Drug Therapy Topics. University of Washington Medical Center. Archived from the original (PDF) on 2013-12-26. Retrieved 25 December 2013.
Sources: en.wikipedia.org
=== Changing sleep position === More than half of people with obstructive sleep apnea have some degree of positional obstructive sleep apnea, meaning that it gets worse when they sleep on their backs. Sleeping on their sides is an effective and cost-effective treatment for positional obstructive sleep apnea.
=== Pleural space pressure === A pneumothorax (collapsed lung) is an abnormal collection of air in the pleural space that causes an uncoupling of the lung from the chest wall. The lung cannot expand against the air pressure inside the pleural space. An easy to understand example is a traumatic pneumothorax, where air enters the pleural space from outside the body, as occurs with puncture to the chest wall. Similarly, scuba divers ascending while holding their breath with their lungs fully inflated can cause air sacs (alveoli) to burst and leak high pressure air into the pleural space.
Microfluidics refers to a system that manipulates a small amount of fluids (10−9 to 10−18 liters) using small channels with sizes of ten to hundreds of micrometres. It is a multidisciplinary field that involves molecular analysis, molecular biology, and microelectronics. It has practical applications in the design of systems that process low volumes of fluids to achieve multiplexing, automation, and high-throughput screening. Microfluidics emerged in the beginning of the 1980s and is used in the development of inkjet printheads, DNA chips, lab-on-a-chip technology, micro-propulsion, and micro-thermal technologies. Typically microfluidic systems transport, mix, separate, or otherwise process fluids. Various applications rely on passive fluid control using capillary forces, in the form of capillary flow modifying elements, akin to flow resistors and flow accelerators. In some applications, external actuation means are additionally used for a directed transport of the media. Examples are rotary drives applying centrifugal forces for the fluid transport on the passive chips. Active microfluidics refers to the defined manipulation of the working fluid by active (micro) components such as micropumps or microvalves. Micropumps supply fluids in a continuous manner or are used for dosing. Microvalves determine the flow direction or the mode of movement of pumped liquids. Often, processes normally carried out in a lab are miniaturised on a single chip, which enhances efficiency and mobility, and reduces sample and reagent volumes.
=== Cancer === A 2020 study found that ADAM10 enhances the proliferation, migration, and invasion of osteosarcoma cells by modulating the E-cadherin/β-catenin signaling pathway, with miR-122-5p identified as a regulatory upstream target of ADAM10, suggesting that the miR-122-5p/ADAM10 axis may represent a potential therapeutic target for osteosarcoma.
This differential equation is the classic equation of motion for charged particles. Together with the particle's initial conditions, it completely determines the particle's motion in space and time in terms of m/Q. Thus mass spectrometers could be thought of as "mass-to-charge spectrometers". When presenting data, it is common to use the (officially) dimensionless m/z, where z is the number of elementary charges (e) on the ion (z=Q/e). This quantity, although it is informally called the mass-to-charge ratio, more accurately speaking represents the ratio of the mass number and the charge number, z.
Sources: en.wikipedia.org
It should first equilibrate to room temperature in a sealed container to prevent condensation on the cold contents. Opening too soon can introduce moisture and reduce stability, and the waiting period depends on vial size and packaging.
Hydrophobic peptides may require buffers, organic cosolvents, or a stepwise solvent approach. Small amounts of acetonitrile, methanol, or dimethyl sulfoxide are sometimes used, followed by dilution into aqueous buffer. The exact solvent system should be tested for the specific sequence.
Single-use aliquots limit freeze-thaw cycling, which can cause aggregation, precipitation, or loss of activity. They also reduce repeated opening of the same container and lower contamination risk. Labeling each aliquot supports traceability and consistent use.
Removing water reduces hydrolytic and some oxidative degradation. Powder forms are generally more stable for long-term storage than solutions. Stability still depends on peptide sequence, residual moisture, and container conditions.